Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Short Interest Update

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRXGet Rating) was the recipient of a significant decline in short interest in October. As of October 31st, there was short interest totalling 915,200 shares, a decline of 6.5% from the October 15th total of 978,700 shares. Based on an average daily trading volume, of 185,600 shares, the short-interest ratio is presently 4.9 days. Approximately 8.1% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, November 11th.

Eagle Pharmaceuticals Trading Up 2.6 %

Shares of EGRX stock opened at $37.56 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.52 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $488.88 million, a P/E ratio of 19.56 and a beta of 0.80. Eagle Pharmaceuticals has a 12-month low of $24.35 and a 12-month high of $56.43. The firm has a 50-day moving average price of $30.56 and a 200 day moving average price of $37.86.

Insiders Place Their Bets

In other news, Director Richard A. Edlin sold 6,800 shares of the stock in a transaction on Tuesday, September 6th. The shares were sold at an average price of $30.99, for a total value of $210,732.00. Following the completion of the transaction, the director now owns 22,600 shares in the company, valued at approximately $700,374. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 28.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Walleye Capital LLC acquired a new stake in shares of Eagle Pharmaceuticals in the first quarter valued at $424,000. Comerica Bank lifted its position in shares of Eagle Pharmaceuticals by 12.1% during the first quarter. Comerica Bank now owns 9,980 shares of the specialty pharmaceutical company’s stock worth $502,000 after purchasing an additional 1,080 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Eagle Pharmaceuticals by 3.1% during the second quarter. Exchange Traded Concepts LLC now owns 30,746 shares of the specialty pharmaceutical company’s stock valued at $1,366,000 after purchasing an additional 912 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Eagle Pharmaceuticals in the first quarter valued at approximately $386,000. Finally, Jackson Creek Investment Advisors LLC bought a new position in Eagle Pharmaceuticals in the 1st quarter worth approximately $1,117,000. 88.49% of the stock is owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

(Get Rating)

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma.

Featured Stories

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.